دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation
David W.M.MullerMBBS, MDaPaulSorajjaMDbAlisonDuncanMBBS, PhDcBrianBetheaMDdGryDahleMDePaulGrayburnMDfVasilisBabaliarosMDgMayraGuerreroMDhVinod H.ThouraniMDiFrancescoBedogniMDjPaoloDentiMDkNicolasDumonteilMDlThomasModineMDmPaulJanszMBBS, PhDnMichael L.ChuangMDoPhilippBlankeMDpJonathonLeipsicMDpVinayBadhwarMDq
doi : 10.1016/j.jacc.2021.08.060
Volume 78, Issue 19, 9 November 2021, Pages 1847-1859
Transcatheter mitral valve replacement (TMVR) is feasible for selected patients with severe mitral regurgitation (MR) who are poor candidates for valve surgery. Intermediate-term to long-term TMVR outcomes have not been reported.
Transcatheter Mitral Valve Replacement: A Need for Better Patient Selection?
JosepRodés-CabauMD, PhDabAnderRegueiroMD, PhDbMichael J.MackMDc
doi : 10.1016/j.jacc.2021.08.062
Volume 78, Issue 19, 9 November 2021, Pages 1860-1862
Surveillance Imaging Following Acute Type A Aortic Dissection
Kevin R.AnMDaCharlesde MestralMD, PhDbcDerrick Y.TamMD, PhDaFengQiuMScdMaralOuzounianMD, PhDaThomas F.LindsayMD, MSceHarindra C.WijeysunderaMD, PhDcfJennifer C.-Y.ChungMD, MSca
doi : 10.1016/j.jacc.2021.08.058
Volume 78, Issue 19, 9 November 2021, Pages 1863-1871
Survivors of acute type A aortic dissection (ATAAD) repair remain at risk for long-term complications. Guidelines recommend postoperative imaging surveillance, but adherence is uncertain.
Towards Tailored Imaging Surveillance for Type A Dissection??
JeanBismuthMDaMariaKatsarouMDabSantiTrimarchiMD, PhDbc
doi : 10.1016/j.jacc.2021.08.055
Volume 78, Issue 19, 9 November 2021, Pages 1872-1874
Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease
GillesRioufolMD, PhDaFrançoisDérimayMD, PhDaFrançoisRoubilleMD, PhDbThibaultPerretMDcPascalMotreffMD, PhDdDenisAngoulvantMD, PhDeYvesCottinMD, PhDfLudovicMeunierMDgLauraCetranMDhGuillaumeCaylaMD, PhDiBrahimHarbaouiMDjJean-YvesWiedemannMDkÉricVan BelleMD, PhDlChristophePouillotMDmNathalieNoirclercMDnJean-FrançoisMorelleMDoFrançois-XavierSotoMDpChristopheCaussinMDqBernardBertrandMDrThierryLefèvreMDsPatrickDupouyMDtPierre-FrançoisLesaultMD, PhDuFranckAlbertMDvOlivierBarthelemyMDwRenéKoningMDxLaurentLeborgneMDyPierreBarnayMDzPhilippeChaponMDaaSébastienArmeroMDbbAntoineLafontMDccChristophePiotMD, PhDddCamilleAmazMSceeBernadetteVazPharmD, MSceeLakhdarBenyahyaPhDeeYvonneVarilloneeMichelOvizeMD, PhDeeNathanMewtonMD, PhDee?GérardFinetMD, PhDa?on behalf of the
doi : 10.1016/j.jacc.2021.08.061
Volume 78, Issue 19, 9 November 2021, Pages 1875-1885
There is limited evidence that fractional flow reserve (FFR) is effective in guiding therapeutic strategy in multivessel coronary artery disease (CAD) beyond prespecified percutaneous coronary intervention or coronary graft surgery candidates.
The Enduring Legacy of Failed Revascularization Trials?
Harold L.DauermanMDaJan G.P.TijssenPhDbGillesMontalescotMD, PhDc
doi : 10.1016/j.jacc.2021.08.059
Volume 78, Issue 19, 9 November 2021, Pages 1886-1889
Predicting Major Adverse Cardiovascular Events in Children With Age-Adjusted NT-proBNP
JonasPalmMDaStefanHoldenriederMD, PhDbGeorgHoffmannMD, PhDbJürgenHörerMD, PhDcdRuibingShiMSceFrankKlawonnPhDefPeterEwertMD, PhDag
doi : 10.1016/j.jacc.2021.08.056
Volume 78, Issue 19, 9 November 2021, Pages 1890-1900
N-terminal pro–B-type natriuretic peptide (NT-proBNP) is frequently used as a valuable prognostic biomarker in cardiac diseases. In children, however, it has not been established because of its strong age dependency. To overcome this obstacle, we recently introduced the zlog value of N-terminal pro–B-type natriuretic peptide (zlog-proBNP) as an age-adjusted reference.
Pediatric Data for Pediatric Heart Failure: Stepping Out on Our Own?
Steven J.KindelMD
doi : 10.1016/j.jacc.2021.09.009
Volume 78, Issue 19, 9 November 2021, Pages 1901-1903
AHA/ACC vs ESC Guidelines for Management of Adults With Congenital Heart Disease: JACC Guideline Comparison
GabrieleEgidy AssenzaMDa?Eric V.KriegerMDb?HelmutBaumgartnerMDcBlancheCupidoMD, MBChBdKonstantinosDimopoulosMD, MSc, PhDeClaudenLouisMD, MSfAdam M.LubertMDgKaren K.StoutMDbAnne MarieValenteMDhKatjaZeppenfeldMD, PhDiAlexander R.OpotowskyMD, MMScg
doi : 10.1016/j.jacc.2021.09.010
Volume 78, Issue 19, 9 November 2021, Pages 1904-1918
The American Heart Association and American College of Cardiology published practice guidelines for the management of adult congenital heart disease in 2018 and the European Society of Cardiology published analogous guidelines in 2020. Although there are broad areas of consensus between the 2 documents, there are important differences that impact patient management. This review discusses key areas of agreement and disagreement between the 2 guidelines, with discussion of possible reasons for disagreement and potential implications.
Socioeconomic Determinants of Health and Cardiovascular Outcomes in Women: JACC Review Topic of the Week
Kathryn J.LindleyMDaNiti R.AggarwalMDbJoan E.BrillerMDcMelinda B.DavisMDdPaulDouglassMDeKelly C.EppsMDfJerome L.FlegMDgSharonneHayesMDhDiptiItchhaporiaMDiZainabMahmoudMDaGlaucia MariaMoraes De OliveiraMD, MSc, PhDjModele O.OgunniyiMD, MPHkOdaymeQuesadaMDlAndrea M.RussoMDmJyotiSharmaMDnMalissa J.WoodMDoAmerican College of Cardiology Cardiovascular Disease in Women Committee and the American College of Cardiology Health Equity Taskforce
doi : 10.1016/j.jacc.2021.09.011
Volume 78, Issue 19, 9 November 2021, Pages 1919-1929
Socioeconomic disparities in cardiovascular risk factors and outcomes exist among women, particularly those of minority racial or ethnic backgrounds. Barriers to optimal cardiovascular health begin early in life—with inadequate access to effective contraception, postpartum follow-up, and maternity leave—and result in excess rates of myocardial infarction, stroke, and cardiovascular death in at-risk populations. Contributing factors include reduced access to care, low levels of income and social support, and lack of diversity among cardiology clinicians and within clinical trials. These barriers can be mitigated by optimizing care access via policy change and improving physical access to care in women with geographic or transportation limitations. Addressing structural racism through policy change and bolstering structured community support systems will be key to reducing adverse cardiovascular outcomes among women of racial and ethnic minorities. Diversification of the cardiology workforce to more closely represent the patients we serve will be beneficial to all women.
In Memoriam: A Tribute to Attilio Maseri
FilippoCreaMD, PhDabEugeneBraunwaldMDcdValentinFusterMD, PhDef
doi : 10.1016/j.jacc.2021.10.001
Volume 78, Issue 19, 9 November 2021, Pages 1930-1933
Impact of Age and Sex on Treatment and Outcomes Following Myocardial Infarction
MishaDaganMMed(ClinEpi), MDDiem T.DinhPhDJuliaStehliMDSarahZamanMBBS, PhDAngelaBrennanRNChristianneTanMBBSDannyLiewMBBS, PhDChristopher M.ReidPhDDionStubMBBS, PhDDavid M.KayeMBBS, PhDJeffreyLefkovitsMBBSStephen J.DuffyMBBS, PhDVictorian Cardiac Outcomes Registry
doi : 10.1016/j.jacc.2021.08.057
Volume 78, Issue 19, 9 November 2021, Pages 1934-1936
Left Atrial Appendage Occlusion in Hypertrophic Cardiomyopathy Patients Should Be Taken Into Account
XiongWangMD, PhDPengWangMDHaifengPeiMD, PhD
doi : 10.1016/j.jacc.2021.08.053
Volume 78, Issue 19, 9 November 2021, Page e157
Reply: Left Atrial Appendage Occlusion in Hypertrophic Cardiomyopathy Patients Should Be Taken Into Account
TrevorSimardMDRichard G.JungPhDBenjaminHibbertMD, PhDDavid R.HolmesJr.MDMohamadAlkhouliMD
doi : 10.1016/j.jacc.2021.09.007
Volume 78, Issue 19, 9 November 2021, Page e159
Is Rhythm Control With Medication Unwittingly a Dangerous Proposition for Racial and Ethnic Minorities?
John M.FontaineMD, MBA
doi : 10.1016/j.jacc.2021.07.061
Volume 78, Issue 19, 9 November 2021, Page e161
Racial and Ethnic Representation in Atrial Fibrillation Trials: CABANA and Beyond
TarrynTertulienMD, MScJared W.MagnaniMD, MScUtibe R.EssienMD, MPH
doi : 10.1016/j.jacc.2021.08.054
Volume 78, Issue 19, 9 November 2021, Pages e163-e164
